摘要
目的:研究莪芪抗瘤方对二乙基亚硝胺(DEN)诱导大鼠肝癌过程中相关基因蛋白阳性细胞数的影响。方法:建立DEN诱导大鼠肝癌模型,分别于诱导第12周末和第16周末采用免疫组化染色方法检测莪芪抗瘤方对大鼠肝细胞增殖细胞核抗原(PCNA)、抗癌基因(p53)蛋白阳性表达的影响。结果:p53阳性细胞可见于癌前肝细胞增生结节中;莪芪抗瘤方在诱导第12周末和第16周末均能明显抑制p53的阳性表达(P<0.05),显著降低PCNA(P<0.01)。结论:在DEN诱导大鼠肝癌模型过程中,于肝癌癌前病变时p53即发生了基因突变、参与肝癌的形成。莪芪抗瘤方可抑制大鼠诱癌过程中肝细胞的增殖活性和p53的突变,从而延缓肝癌的形成。
Objective： To study the influence of the Ewi-anticarcinogen Prescription on associated gene protein in process of rat hepatocarcinoma induced by diethylnitrosamine （DEN）. Methods： Rats hepatocarcinoma model was induced by DEN, while the Eqi-anticarcinogen Prescription was used during the stage. At the end of 12th week and 16th week, the influence of the Eqi-anticarcinogen Prescription on positive expression of PCNA and p53 protein were examined by immuneohistochemical method. Results： The positive expression of p53 protein was occurred in precancerous hyperp lastic nodules; The Eqi-anticarcinogen Prescription can significantly inhibit the overexpression of p53 （P0.05） , and strikingly reduce PCNA （P0.01） at the end of 12th week and 16th week. Conclusion： p53 gene mutation could occur in precancerous stage in DEN-induced liver cancer model and may relate to the initiation of hepartocarcinoma.The Eqi-anticarcinogen Prescription can inhibit the proliferative character of hepatocytes and the mutateon of p53 gene, as well as slow down the process of hepatocarcinoma induced in rats.
出处
《中华中医药杂志》
CAS
CSCD
北大核心
2010年第4期523-526,共4页
China Journal of Traditional Chinese Medicine and Pharmacy
基金
福建省自然基金课题(No.2006J0359)~~
关键词
肝癌
增殖细胞核抗原
抑癌基因蛋白
免疫组化
莪芪抗瘤方
Hepatocarcinoma Proliferating cell nuclear antigen（PCNA） Anti-Oncogene proteins Immunohistochemistry
